1.
Anadón, A., Martínez-Larrañaga, MR., Ares, I. and Martínez MA., Biomarkers of Drug Toxicity and
Safety Evaluation, In Gupta, RC., editor. Biomarkers in Toxicology. 2nd ed. San Diego: Academic
Press; 2019. P. 655-691.
2.
Atkinson, HC. and Waddell, BJ. (1997): Circadian variation in basal plasma corticosterone and
adrenocorticotropin in the rat: sexual dimorphism and changes across the estrous cycle. Endocrinology,
138, 3842-3848.
3.
Bose, HS., Sugawara, T., Strauss, JF 3rd. and Miller, WL. (1996): The pathophysiology and genetics
of congenital lipoid adrenal hyperplasia. N. Engl. J. Med., 335, 1870-1878.
4.
Brändli-Baiocco, A., Balme, E., Bruder, M., Chandra, S., Hellmann, J., Hoenerhoff, MJ., Kambara,
T., Landes, C., Lenz, B., Mense, M., Rittinghausen, S., Satoh, H., Schorsch, F., Seeliger, F., Tanaka,
T., Tsuchitani, M., Wojcinski, Z. and Rosol, TJ. (2018): Nonproliferative and Proliferative Lesions of
the Rat and Mouse Endocrine System. J. Toxicol. Pathol., 31 (3 Suppl); 1S-95S.
5.
Briggs, K., Barber, C., Cases, M., Marc, P., and Steger-Hartmann, T. (2015): Value of shared
preclinical safety studies - The eTOX database. Toxicol. Rep., 2, 210-221.
6.
Burrin, JM., Yeo, TH., Ashby, MJ., and Bloom, SR. (1986): Effect of ketoconazole on
adrenocorticotrophic hormone secretion in vitro and in vivo. J. Endocrinol., 108: 37-41.
7.
Capen CC. Toxic response of the endocrine system. In Klaassen, C., editor. Casarett & Doull’s
toxicology: The basic science of poisons. 7th ed. New York: McGraw-Hill Professional; 2007. p. 807880.
8.
Cavanah, SF. and Dons, RF. (1993): Partial 3 beta-hydroxysteroid dehydrogenase deficiency
presenting as new-onset gynecomastia in a eugonadal adult male. Metabolism, 42, 65-68.
9.
Charmandari, E., Nicolaides, NC. and Chrousos, GP. (2014): Adrenal insufficiency. Lancet, 383:
2152-2167.
99
10. Chung, S., Son, GH. and Kim, K. (2011): Circadian rhythm of adrenal glucocorticoid: its regulation
and clinical implications. Biochim. Biophys. Acta., 1812, 581-591.
11. Colby, HD., Skelton, FR. and Brownie, AC. (1970): Metopirone-induced hypertension in the rat.
Endocrinology, 86, 620-628.
12. Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G. and Pangalos, MN.
(2014): Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.
Nat. Rev. Drug Discov., 13: 419-431.
13. Cooke, CR., Whelton, PK., Moore, MA., Caputo, RA., Bledsoe, T. and Walker, WG. (1979):
Dissociation of the diurnal variation of aldosterone and cortisol in anephric subjects. Kidney Int., 15,
669-675.
14. Elmore, SA. (2012): Enhanced histopathology of the immune system: a review and update. Toxicol.
Pathol., 40, 148-156.
15. Engelhardt, D., Dörr, G., Jaspers, C. and Knorr, D. (1985): Ketoconazole blocks cortisol secretion in
man by inhibition of adrenal 11 beta-hydroxylase. Klin. Wochenschr., 63, 607–661.
16. Engelhardt, D., Weber, MM., Miksch, T., Abedinpour, F. and Jaspers, C. (1991): The influence of
ketoconazole on human adrenal steroidogenesis: incubation studies with tissue slices. Clin. Endocrinol
(Oxf)., 35, 163-168.
17. Gotoh, H., Sagai, T., Hata, J., Shiroishi, T. and Moriwaki, K. (1988): Steroid 21-hydroxylase
deficiency in mice. Endocrinology, 123, 1923-1927.
18. Gwynne, JT., Mahaffee, D., Brewer, HB Jr. and Ney, RL. (1976): Adrenal cholesterol uptake from
plasma lipoproteins: regulation by corticotropin. Proc. Natl. Acad. Sci. USA., 73, 4329-4333.
19. Hamdy DA. and Brocks DR. (2009): Nonlinear stereoselective pharmacokinetics of ketoconazole in
rat after administration of racemate. Chirality, 21, 704-712.
100
20. Hanukoglu, I. (1992): Steroidogenic enzymes: structure, function, and role in regulation of steroid
hormone biosynthesis. J. Steroid Biochem. Mol. Biol., 43, 779-804.
21. Harvey, PW. (2016): Adrenocortical endocrine disruption. J Steroid Biochem Mol Biol., 155, 199206.
22. Harvey, PW. and Everett, DJ. (2003): The adrenal cortex and steroidogenesis as cellular and molecular
targets for toxicity: critical omissions from regulatory endocrine disrupter screening strategies for
human health? J. Appl. Toxicol., 23, 81–87.
23. Harvey, PW. and Sutcliffe, C. (2010): Adrenocortical hypertrophy: establishing cause and
toxicological significance. J. Appl. Toxicol., 30, 617-626.
24. Higashi, Y., Omura, M., Suzuki, K., Inano, H., and Oshima, H. (1987): Ketoconazole as a possible
universal inhibitor of cytochrome P-450 dependent enzymes: its mode of inhibition. Endocrinol. Jpn.,
34, 105-115.
25. Hille, UE., Zimmer, C., Vock, CA. and Hartmann, RW. (2010): First Selective CYP11B1 Inhibitors
for the Treatment of Cortisol-Dependent Diseases. ACS Med. ChemLett., 2, 2-6.
26. Hinson, JP. and Raven, PW. (2006): Effects of endocrine-disrupting chemicals on adrenal function.
Best Pract. Res. Clin. Endocrinol. Metab., 20, 111–120.
27. Holt, RIG. An overview of human adrenal dysfunction. In Harvey, PW., Everett, DV., Springall, CJ.,
editors. Adrenal toxicology. New York: Informa healthcare; 2008. p. 39-76.
28. Inomata, A. and Sasano, H. (2015): Practical approaches for evaluating adrenal toxicity in nonclinical
safety assessment. J. Toxicol. Pathol., 28, 125-132.
29. Johansson, MK., Sanderson, JT. and Lund, BO. (2002): Effects of 3-MeSO2-DDE and some CYP
inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line.
Toxicol. In Vitro, 16, 113–121.
101
30. Koal, T., Schmiederer, D., Pham-Tuan, H., Röhring, C. and Rauh, M. (2012): Standardized LCMS/MS based steroid hormone profile-analysis. J. Steroid Biochem. Mol. Biol., 129, 129-138.
31. Kushnir, MM., Rockwood, AL. and Bergquist, J. (2010): Liquid chromatography–tandem mass
spectrometry applications in endocrinology. Mass Spectrom. Rev., 29, 480–502.
32. Latendresse, JR., Azhar, S., Brooks, CL. and Capen, CC. (1993): Pathogenesis of cholesteryl lipidosis
of adrenocortical and ovarian interstitial cells in F344 rats caused by tricresyl phosphate and butylated
triphenyl phosphate. Toxicol. Appl. Pharmacol., 122, 281-289.
33. Latendresse, JR., Brooks, CL., Capen, CC. (1995): Toxic effects of butylated triphenyl phosphatebased hydraulic fluid and tricresyl phosphate in female F344 rats. Vet. Pathol., 32, 394-402.
34. Li, H., Brochu, M., Wang, SP., Rochdi, L., Côté, M., Mitchell, G. and Gallo-Payet N. (2002):
Hormone-sensitive lipase deficiency in mice causes lipid storage in the adrenal cortex and impaired
corticosterone response to corticotropin stimulation. Endocrinology, 143, 3333-3340.
35. Li, L., Vashisht, K., Boisclair, J., Li, W., Lin, TH., Schmid, HA., Kluwe, W., Schoenfeld, H. and
Hoffmann, P. (2015): Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in
combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats.
Toxicol. Appl. Pharmacol., 286, 224-233.
36. Loose, DS., Kan, PB., Hirst, MA., Marcus, RA. and Feldman, D. (1983): Ketoconazole blocks adrenal
steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J. Clin. Invest., 71, 1495-1499.
37. Maeda, N., Tanaka, E., Suzuki, T., Okumura, K., Nomura, S., Miyasho, T., Haeno, S. and Yokota, H.
(2013): Accurate determination of tissue steroid hormones, precursors and conjugates in adult male
rat. J. Biochem., 153, 63-71.
38. McGee, JP., and Shaw, PN. (1992): The pharmacokinetics of trilostane and ketotrilostane in an
interconverting system in the rat. Pharm. Res., 9, 464-468.
102
39. Miller, WL. and Bose, HS. (2011): Early steps in steroidogenesis: intracellular cholesterol trafficking.
J. Lipid Res., 52, 2111–2135.
40. Miller, WL., Auchus, RJ. (2011). The molecular biology, biochemistry, and physiology of human
steroidogenesis and its disorders. Endocr. Rev., 32, 81-151.
41. Mohn, CE., Fernandez-Solari, J., De Laurentiis, A., Prestifilippo, JP., de la Cal, C., Funk, R., Bornstein,
SR., McCann, SM. and Rettori, V. (2005): The rapid release of corticosterone from the adrenal
induced by ACTH is mediated by nitric oxide acting by prostaglandin E2. Proc. Natl. Acad. Sci. USA,
102, 6213-6218.
42. Mullins, LJ., Peter, A., Wrobel, N., McNeilly, JR., McNeilly, AS., Al-Dujaili, EA., Brownstein, DG.,
Mullins, JJ., Kenyon, CJ. (2009). CYP11b1 null mouse, a model of congenital adrenal hyperplasia. J.
Biol. Chem., 284, 3925-3934.
43. National Toxicology Program (1994). Toxicology and Carcinogenesis Studies of tricresyl phosphate
(CAS No. 1330-78-5) in F344/N Rats and B6C3F1 Mice (Gavage and Feed Studies). NTP TR 433,
NIH Publication No. 94-3164., NIEHS, Research Triangle Park, NC.
44. New, MI. (2004): An update of congenital adrenal hyperplasia. Ann. N. Y. Acad. Sci., 1038, 14-43.
45. Ng, W., Metushi, IG., and Uetrecht, J. (2013): Hepatic effects of aminoglutethimide: a model aromatic
amine. J. Immunotoxicol., 12, 24-32.
46. Nimkarn, S. and New, M. I. (2008): Steroid 11beta- hydroxylase deficiency congenital adrenal
hyperplasia. Trends Endocrinol. Metab., 19, 96-99.
47. Nishizato, Y., Imai, S., Okahashi, N., Yabunaka, A., Kunimatsu, T., Kikuchi, K., and Yabuki M.
(2014): Translational research into species differences of endocrine toxicity via steroidogenesis
inhibition by SMP-028--for human safety in clinical study. Toxicol. Appl. Pharmacol., 276, 213-219.
103
48. Obert, LA., Sobocinski, GP., Bobrowski, WF., Metz, AL., Rolsma, MD., Altrogge, DM. and Dunstan,
RW. (2007): An immunohistochemical approach to differentiate hepatic lipidosis from hepatic
phospholipidosis in rats. Toxicol. Pathol., 35, 728-734.
49. Potts, GO., Creange, JE., Hardomg, HR., and Schane, HP. (1978): Trilostane, an orally active inhibitor
of steroid biosynthesis. Steroids, 32, 257-267.
50. Ribelin, WE. (1984): The effects of drugs and chemicals upon the structure of the adrenal gland.
Fundam. Appl. Toxicol., 4, 105–119.
51. Roberts, RA, Kavanagh, SL., Mellor, HR., Pollard, CE., Robinson, S. and Platz SJ. (2014): Reducing
attrition in drug development: smart loading preclinical safety assessment. Drug Discov. Today, 19:
341-347.
52. Rosol, TJ., Yarrington, JT., Latendresse, J. and Capen, CC. (2001): Adrenal gland: structure, function,
and mechanisms of toxicity. Toxicol. Pathol., 29, 41–48.
53. Sanderson, JT. (2006): The steroid hormone biosynthesis pathway as a target for endocrine-disrupting
chemicals. Toxicol. Sci., 94, 3-21.
54. Schöneshöfer, M., Schefzig, B. and Arabin, S. (1980): Short-term kinetics of serum adrenal steroids
and plasma ACTH after a single dose of metyrapone in man. J. Endocrinol. Invest., 3, 229-236.
55. Shackleton, C. (2010): Clinical steroid mass spectrometry: a 45-year history culminating in HPLC–
MS/MS becoming an essential tool for patient diagnosis. J. Steroid Biochem. Mol. Biol., 121, 481–
490.
56. Shin, JH., Moon, HJ., Kang, IH., Kim, TS., Kim, IY., Park, IS., Kim, HS., Jeung, EB. and Han, SY.
(2006): Repeated 28-day oral toxicity study of ketoconazole in rats based on the draft protocol for the
"Enhanced OECD Test Guideline No. 407" to detect endocrine effects. Arch. Toxicol., 80: 797-803.
104
57. Szabó, D., Gláz, E., Kelemen, J. (1974): Subcellular localisation of adrenal cholesterol by
autoradiography and digitonin reaction after aminoglutethimide-induced inhibiton of corticosterone
synthesis. Histochemie., 38, 213-221.
58. Tamura, T., Yokoi, R., Okuhara, Y., Harada, C., Terashima, Y., Hayashi, M., Nagasawa, T., Onozato,
T., Kobayashi, K., Kuroda, J., Kusama, H. (2009): Collaborative work on evaluation of ovarian
toxicity. 2) Two- or four-week repeated dose studies and fertility study of mifepristone in female rats.
J. Toxicol. Sci., 34 Suppl. 1, 31-42.
59. Thomas, JL., Bucholtz, KM., Kacsoh, B. (2011): Selective inhibition of human 3β-hydroxysteroid
dehydrogenase type 1 as a potential treatment for breast cancer. J. Steroid Biochem. Mol. Biol., 125,
57-65.
60. Umberkoman-Wiita, B., Hansen, S., Herbert, J. and Moore, GF. (1981): Circadian rhythms in serum
and CSF cortisol of rhesus monkeys, and their modulation by timed injections of L-5hydroxytryptophan. Brain Res., 222, 235-252.
61. Vinson, GP. (2011): The mislabelling of deoxycorticosterone: making sense of corticosteroid structure
and function. J. Endocrinol., 211, 3-16.
62. White, PC., Curnow, KM. and Pascoe, L. (1994): Disorders of steroid 11 beta-hydroxylase isozymes.
Endocr. Rev., 15, 421-438.
63. Wickramaratne, GA., Foster, JR., Ellis, MK. and Tomenson, JA. (1998): Molinate: rodent
reproductive toxicity and its relevance to humans--a review. Regul. Toxicol. Pharmacol., 27, 112-118.
64. Yan, Z., Rafferty, B., Caldwell, GW. and Masucci, JA. (2002): Rapidly distinguishing reversible and
irreversible CYP450 inhibitors by using fluorometric kinetic analyses. Eur. J. Drug Metab.
Pharmacokinet., 27, 281–287.
105
65. Yarrington, JT. and Reindel, JF. (1996): Chemically induced adrenocortical degenerative lesions. In:
Jones, TC., Capen, CC. and Mohr, U., editors. Monographs on pathology of laboratory animals,
endocrine system. 2nd ed. New York: Springer; 1996, p. 467-476.
106
...
論文の公開元へ
